Stocks · Healthcare · Biotechnology
Trevi Therapeutics, Inc. TRVI
$13.91 -1.90% Close, Oct 2, 2026 · NASDAQ · Market cap $1.97B
Next earnings report: Nov 12, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The diluted share count rose 20.1% in a year.
- The company holds net cash of $53.7M (cash above total debt).
- Over the past year the stock returned +48.0%, ahead of the S&P 500 by 32.9 percentage points.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 49%
- Accruals (lower is better)Bottom 16%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 37%
- Free-cash-flow yieldTop 42%
- EBITDA / enterprise valueTop 45%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 23%
- 6-month returnTop 42%
- 1-year return vs S&P 500Top 28%
- Distance from 52-week highTop 49%
- Trend checklist (0–4)Bottom 38%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 43%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 35%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 49%
- Maximum drawdown, 3 yearsTop 27%
- Beta vs S&P 500 (lower is better)Top 18%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -18.5% | — | Top 49% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.14%
- Shareholder yield
- -0.14%
- Share count change, 1 year
- +20.1%
- Share count change, 3-year CAGR
- +16.6%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- +7.7%
- Average 2-day reaction, last 8
- +0.1%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $29.67
- Target vs current price
- +113.3%
- Analysts with a rating
- 18
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -0.5% | -0.8% | -4.9% | -8.6% | — |
| May 5, 2026 | -28.6% | +1.9% | +3.5% | -6.1% | +28.0% |
| Mar 17, 2026 | +40.0% | +0.3% | -3.6% | +25.8% | +20.1% |
| Nov 13, 2025 | +20.0% | -3.3% | -6.8% | +11.1% | -5.1% |
| Aug 7, 2025 | +10.0% | +0.4% | +4.5% | -0.6% | +53.6% |
| May 8, 2025 | +30.8% | -0.9% | -7.1% | +1.2% | +12.5% |
| Mar 18, 2025 | +8.3% | +0.3% | -2.1% | -9.0% | -4.4% |
| Nov 6, 2024 | -8.3% | +2.6% | -0.7% | -13.9% | +35.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.11 | -$0.11 | -0.5% | — |
| May 5, 2026 | -$0.09 | -$0.07 | -28.6% | — |
| Mar 17, 2026 | -$0.06 | -$0.10 | +40.0% | — |
| Nov 13, 2025 | -$0.08 | -$0.10 | +20.0% | — |
| Aug 7, 2025 | -$0.09 | -$0.10 | +10.0% | — |
| May 8, 2025 | -$0.09 | -$0.13 | +30.8% | — |
| Mar 18, 2025 | -$0.11 | -$0.12 | +8.3% | — |
| Nov 6, 2024 | -$0.13 | -$0.12 | -8.3% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -1.99% | — | — | Top 42% |
| Earnings yield | -2.43% | — | — | Top 37% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -6.3%
- 200-day average slope (20 days)
- +1.9%
- Distance from 50-day average
- -17.5%
- Distance from 200-day average
- -2.5%
- RSI (14)
- 26.1
- Relative volume
- 1.21×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 56.1%
- Volatility vs own 5-year history
- 6th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.55
- Correlation with S&P 500
- 0.11
- Current drawdown from 1-year high
- -28.7%
- Maximum drawdown, 3 years
- -53.2%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Sep 30, 2020 | Feb 23, 2022 | -88.6% | 352 days | 114 days (Aug 8, 2022) |
| Aug 8, 2022 | Nov 28, 2023 | -75.1% | 329 days | 265 days (Dec 17, 2024) |
| Dec 10, 2025 | Jan 23, 2026 | -29.5% | 29 days | 56 days (Apr 15, 2026) |
| Jul 7, 2026 | Oct 2, 2026 | -28.7% | 62 days | Not yet recovered |
| Jun 6, 2025 | Jun 30, 2025 | -22.5% | 15 days | 16 days (Jul 23, 2025) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.97B
- EPS, diluted (TTM)
- -$0.34
- Revenue (TTM)
- $0
- 52-week range
- $9.28 – $20.22
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$32.5M | -$29.9M | -$33.9M | -$51.5M | -$49.3M |
| Net income | -$33.9M | -$29.2M | -$29.1M | -$47.9M | -$42.8M |
| EPS (diluted) | -$1.49 | -$0.45 | -$0.29 | -$0.47 | -$0.29 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.2M | -$11.4M | -$10.3M | -$12.3M | -$11.8M | -$8.3M | -$13.2M | -$17.8M |
| EPS (diluted) | -$0.13 | -$0.11 | -$0.09 | -$0.09 | -$0.08 | -$0.06 | -$0.09 | -$0.11 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$28.9M | -$28.2M | -$31.7M | -$38.3M | -$42.1M |
| Capital expenditure | $0 | -$159,000 | -$137,000 | -$35,000 | -$12,000 |
| Free cash flow | -$28.9M | -$28.3M | -$31.8M | -$38.3M | -$42.1M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $21.2M | $105.4M | $1.7M | $61.1M | $120.3M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $318.9M
- Total assets
- $330.5M
- Total liabilities
- $9.0M
- Total debt
- $605,000
- Net debt
- -$53.7M
- Shareholders’ equity
- $321.5M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 12,070,625
- Days to cover
- 8.79
- Change vs previous report
- +0.5%
FINRA short interest, settlement date Sep 15, 2026.